DUBLIN--(BUSINESS WIRE)--Jun 29, 2020--

ResearchAndMarkets.com has published a new article "FDA Allows Remote Review of Digital Pathology Slides"

The US Food and Drug Administration has temporarily relaxed regulations around digital pathology devices to facilitate remote review of scanned slide images during the pandemic. This can help to reduce pathologists risk of exposure to the virus and minimize disruptions to pathology services. Previously, pathologists were required to work from a healthcare setting that held a current CLIA license.

The FDA has also tightened requirements for antibody tests featured on the notification list of tests offered under the Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency. Companies who wish to be featured will have to submit data on their tests’ accuracy and how it will be marketed. In late May the FDA removed more than 30 tests from the notification list. Some were withdrawn voluntarily by the manufacturer while others were removed because there is no pending or issued Emergency Use Authorization. The FDA does not expect that these tests will be marketed or distributed.

To see the full article and a list of related reports on the market, visit "FDA Allows Remote Review of Digital Pathology Slides"

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200629005258/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 06/29/2020 04:14 AM/DISC: 06/29/2020 04:14 AM


Copyright Business Wire 2020.

Recommended for you

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Thank you for reading!

Please log in, or sign up for a new account and purchase a subscription to read or post comments.